E
Estrella Immunopharma, Inc. (ESLA)
NCM – Real Time Price. Currency in USD
0.98
+0.03 (3.45%)
At close: Jun 26, 2026, 4:00 PM EDT
0.96
-0.03 (-2.55%)
After-hours: Jun 26, 2026, 7:42 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.98
+0.03 (3.45%)
At close: Jun 26, 2026, 4:00 PM EDT
0.96
-0.03 (-2.55%)
After-hours: Jun 26, 2026, 7:42 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Cash reserves $1.9M barely cover the upcoming debt maturities $0.0
Total current liabilities $8.9M surpass Total current assets $2.2M, signaling liquidity issues
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$6.7M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 0.24 | 6.05 | 2.0 | |
| Quick ratio | 0.24 | 5.63 | 2.0 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 3.2 | |||
| METRIC | 2021 | 2022 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -249K | -2M | -9M | -13M | -13M |
| Net Income | -248K | -996K | -9M | -13M | -13M |
| EBITDA | -249K | -2M | -9M | -13M | -13M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -17.31 | 1.0 |
| Next quarter | N/A | 36.84 | 5.5 |
| Current year | N/A | N/A | 1.0 |
| Next year | N/A | N/A | 1.0 |
| Weighted average score | 2.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -273.79 | 26.32 | -3673.73 | 5.5 |
| Y/Y | 999 | -8.91 | -16.66 | -1337.39 | 3.3 |
| 3y average | 999 | -379.49 | N/A | -128.58 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 3.3 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |